Company: SHPH
Filing Date: 2025-02-26
Form Type: 10-K
Source: 0001493152-25-008300
Chunk: 72

Company: Shuttle Pharmaceuticals Holdings, Inc.
Filing Date: 2025-02-26
Form: 10-K
Item: Item 1
Chunk 72
---
 such new or revised accounting standard. Corresponding changes have been made to the Exchange
    Act, which relates to periodic reporting requirements, which would be applicable if the Company were required to comply with them.

    ●
    As
    long as we are an EGC, we may comply with Item 402 of Regulation S-K, which requires extensive quantitative and qualitative disclosure
    regarding executive compensation, by disclosing the more limited information required of a “smaller reporting company.”

    ●
    The
    Jobs Act will also exempt us from the following additional compensation-related disclosure provisions that were imposed on U.S. public
    companies pursuant to the Dodd-Frank Act: (i) the advisory vote on executive compensation required by Section 14A(a) of the Exchange
    Act; (ii) the requirements of Section 14A(b) of the Exchange Act relating to stockholders advisory votes on “golden parachute”
    compensation; (iii) the requirements of Section 14(i) of the Exchange Act as to disclosure relating to the relationship between executive
    compensation and our financial performance; and (iv) the requirement of Section 953(b)(1) of the Dodd-Frank Act, which requires disclosure
    as to the relationship between the compensation of our chief executive officer and median employee pay.

44

Our
stock price may be volatile, and purchasers of our common stock could incur substantial losses.

Since
commencement of trading on Nasdaq, our stock price has been extremely volatile. As a result of this volatility, investors may not be
able to sell their common stock at or above the price when they purchased our common stock. The market price for our common stock may
be influenced by many factors, including the other risks described in this section of this Annual Report entitled “Risk Factors”
and the following:

    ●
    the
    success of competitive products or technologies;

    ●
    results
    of preclinical and clinical studies of our product candidates, or those of our competitors, our existing collaborator or any future
    collaborators;

    ●
    regulatory
    or legal developments in the U.S. and other countries, especially changes in laws or regulations applicable to our products;

    ●
    introductions
    and announcements of new products by us, our commercialization partners, or our competitors, and the timing of these introductions
    or announcements;

    ●
    actions
    taken by regulatory agencies with respect to our products, clinical studies, manufacturing process or sales and